Debulking surgery for small intestine neuroendocrine tumors
https://doi.org/10.62546/3034-1477-2024-2-4-52-66
Abstract
Neuroendocrine tumors (NETs) include heterogeneous neoplasms that can be functional or symptomatically active (functioning) or non-functioning. The overall incidence of NETs is growing faster than the incidence of all human malignancies. NETs are the second most common gastrointestinal cancers, characterized by frequent liver metastasis, which is a major factor affecting the quality of life and significant survival of patients. Cytoreductive treatment of liver metastases (NELM) is the method of choice aimed at ensuring prolongation of patient survival and improving control of hormonal symptoms resistant to conservative therapy. Surgical resection of metastases is indicated in patients with well-differentiated (G1/G2) tumors, while its feasibility and complexity in severity dictate the degree of liver involvement. As a result of advances in surgical techniques in recent years, 1- and 2-stage or repeat liver resections are performed safely and effectively by surgeons with the treatment of NETs. The wide range of interventional radiological treatments for NELM with limitations requires reasons, which is the basis for adjunctive or alternative surgery. In general, liver-directed therapies can precede the administration of systemic molecular targeted agents and chemotherapy for patients with metastatic stage and severe liver disease, which leads to the fact that patients continue to be treated only with somatostatin analogues (SAA). Cytoreductive surgery of NETs is not limited to liver metastases, but is also used in peritoneal carcinomatosis. The large variability of clinical manifestations and the prevalence of the tumor process determine the need for an individual regimen for each patient within the framework of the MDT. In this article, we discuss the surgical approach to metastatic small bowel NETs: primary tumor, liver metastases and peritoneal carcinomatosis.
About the Authors
M. S. Dinikin
St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Dinikin Mikhail Sergeyevich
56 Veteranov Ave., St. Petersburg, 198255, Russia
A. K. Ivanova
St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Anastasia K. Ivanova
56 Veteranov Ave., St. Petersburg, 198255, Russia
R. V. Orlova
St. Petersburg City Clinical Oncology Dispensary; St. Petersburg State University
Russian Federation
Russian Federation
Rashida V. Orlova
56 Veteranov Ave., St. Petersburg, 198255, Russia
Yu. V. Pelipas
St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Yuri V. Pelipas
56 Veteranov Ave., St. Petersburg, 198255, Russia
References
1. Pavel M., Oberg K. et al. ESMO Guidelines Committee. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2020. Vol. 31. Р. 844–860. doi: 10.1016/j.annonc.2020.03.304.
2. Clift A.K., Kidd M. et. al. Neuroendocrine Neoplasms of the Small Bowel and Pancreas // Neuroendocrinology. 2020. Vol. 110. Р. 444–476. doi: 10.1159/000503721.
3. Modlin I.M., Shapiro M.D., Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors // Hum. Pathol. 2004. Vol. 35. Р. 1440–1451. doi: 10.1016/j.humpath.2004.09.018.
4. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors // Cancer. 2003. Vol. 97. Р. 934–959.
5. Kulke M.H., Shah M.H. et al. Neuroendocrine tumors, version 1.2015 // J. Natl. Compr. Canc Netw. 2015. Vol. 13. Р. 78–108.
6. Dasari A., Shen C., Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States // JAMA Oncol. 2017. Vol. 3, No. 10. Р. 1335–1342.
7. Артамонова Е.В., Горбунова В.А., Делекторская В.В. и др. Нейроэндокринные неоплазии желудочно-кишечного тракта и поджелудочной железы. Практические рекомендации RUSSCO, часть 1.1 // Злокачественные опухоли. 2024. Т. 14, № 3s2. С. 427–444.
8. https://pubmed.ncbi.nlm.nih.gov/?term=small%20intestine%20neuroendocrine%20tumor&sort=date&timeline=expanded.
9. Boudreaux J.P., Wang Y.Z., Diebold A.E. et al. A single institution’s experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroen-docrine tumors // J. Am. Coll Surg. 2014. Vol. 218. Р. 837–844.
10. Vinik A., Moattari A.R. Use of somatostatin analog in management of carcinoid syndrome // Dig. Dis. Sci. 1989. Vol. 34, No. 3. Р. 14–27. doi: 10.1007/BF01536042. PMID: 2920654.
11. Barsouk A., Rawla P., Barsouk A., Thandra K.C. Epidemiology of Cancers of the Small Intestine: Trends, Risk Factors, and Prevention // Med. Sci. (Basel). 2019. Vol. 7. PMID: 30884915 DOI: 10.3390/medsci7030046.
12. Norlen O., Stalberg P., Oberg K. et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center // World J. Surg. 2012. Vol. 36. Р. 1419–1431.
13. Howe J.R., Cardona K., Fraker D.L. et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society (NANETS) // Pancreas. 2017. Vol. 46. Р. 715–731.
14. Grozinsky-Glasberg S., Davar J., Hofland J. et al. European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease // J. Neuroendocrinol. 2022. Vol. 34, No. 7. e13146.
15. Farley H.A., Pommier R.F. Treatment of neuroendocrine liver metastases // Surg. Oncol. Clin. N. Am. 2016. Vol. 25, No. 1. Р. 217–225.
16. Pavel M., O’Toole D., Costa F. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site // Neuroendocrinology 2016. Vol. 103, No. 2. Р. 172–185.
17. Kelz R.R., Fraker D.L. Metastatic carcinoid: don’t forget the surgical consultation // Surgery. 2014. Vol. 156, No. 6. Р. 1367–1368.
18. Glazer E.S., Tseng J.F., Al-Refaie W. et al. Long-term survival after surgical management of neuroendocrine hepatic metastases // HPB (Oxford). 2010. Vol. 12, No. 6. Р. 427–433.
19. Graff-Baker A.N., Sauer D.A., Pommier S.J. et al. Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients // Surgery. 2014. Vol. 156, No. 6. Р. 1369–1376.
20. Lamarca A., Bartsch D.K. еt al. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours // J. Neuroendocrinol. 2024. Vol. 36, No. 9. Р. 13423. doi: 10.1111/jne.13423.
21. Niederle B., Pape U.F. et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum // Neuroendocrinology. 2016. Vol. 103. Р. 125–138. doi: 10.1159/000443170.
22. Lardière-Deguelte S., de Mestier L., Appéré F. et al. Toward a Preoperative Classification of Lymph Node Metastases in Patients with Small Intestinal Neuroendocrine Tumors in the Era of Intestinal-Sparing Surgery // Neuroendocrinology. 2016. Vol. 103. Р. 552–559. doi: 10.1159/000441423.
23. Moris D., Ntanasis-Stathopoulos I., Tsilimigras D.I., Vagios S., Karamitros A., Karaolanis G., Griniatsos J., Papalampros A., Papaconstantinou I., Glantzounis G.K. et al. Update on Surgical Management of Small Bowel Neuroendocrine Tumors // Anticancer Res. 2018. Vol. 38. Р. 1267–1278. doi: 10.21873/anticanres.12349.
24. De Mestier L., Lepage C., Baudin E. et al. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR) // Dig. Liver Dis. 2020. Vol. 52. Р. 473–492. doi: 10.1016/j.dld.2020.02.011.
25. Keck K.J., Maxwell J.E., Utria A.F. et al. The distal predilection of small bowel neuroendocrine tumors // Ann. Surg. Oncol. 2018. Vol. 25. Р. 3207–3213. doi.org/10.1245/s10434-018-6676-2.
26. Pasquer A., Walter T., Hervieu V. et al. Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis // Ann. Surg. Oncol. 2015. Vol. 22, No. 3. Р. 742–749. doi: 10.1245/s10434-015-4620-2.
27. Strosberg J., Weber J.M., Feldman M. et al. Prognostic validity of the american joint committee on Cancer staging classification for midgut neuroendocrine tumors // J. Clin. Oncol. 2013. Vol. 31. Р. 420–425. doi.org/10.1200/JCO.2012.44.5924.
28. Ohrvall U., Eriksson B., Juhlin C. et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J. Surg. 2000. Nov. Vol. 24 (11). P. 1402–1408. doi: 10.1007/s002680010232.
29. Kaltsas G.A., Besser G.M., Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors // Endocr. Rev. 2004. Vol. 25, No. 3. Р. 458–511.
30. Sarmiento J.M., Heywood G., Rubin J. et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival // J. Am. Coll Surg. 2003. Vol. 197, No. 1. Р. 29–37.
31. Kulkarni R., Kabir I., Hodson J. et al. Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: A systematic review and meta-analysis // Ann. Hepatobiliary Pancreat Surg. 2022. Vol. 26, No. 1. Р. 31–39. doi: 10.14701/ahbps.21-101.
32. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors // Gastroenterology. 2008. Vol. 135. Р. 1469–1492.
33. Chamberlain R.S., Canes D., Brown K.T. et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? // J. Am. Coll Surg. 2000. Vol. 190. Р. 432–445.
34. Maxwell J.E., Sherman S.K., O’Dorisio T.M. et al. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? // Surgery. 2016. Vol. 159. Р. 320–333.
35. Chambers A.J., Pasieka J.L., Dixon E. et al. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors // Surgery. 2008. Vol. 144. Р. 645–651.
36. Lewis A., Raoof M., Ituarte PHG. et al. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment // Ann. Surg. 2019. Vol. 270, No. 6. Р. 1131–1137. doi: 10.1097/SLA.0000000000002809.
37. Caplin M.E., Pavel M., Ćwikła J.B. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors // N. Engl. J. Med. 2014. Vol. 371. Р. 224–233.
38. Rinke A., Muller H.H., Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group // J. Clin. Oncol. 2009. Vol. 27. Р. 4656–4663.
39. Strosberg J., El-Haddad G., Wolin E. et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors // N. Engl. J. Med. 2017. Vol. 376. Р. 125–135.
40. Yao J.C., Fazio N., Singh S. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study // Lancet. 2016. Vol. 387. Р. 968–977.
41. Makridis C., Rastad J., Oberg K. et al. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors // World J. Surg. 1996. Vol. 20. Р. 900–906.
42. Hellman P., Lundstrom T., Ohrvall U. et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases // World J. Surg. 2002. Vol. 26. Р. 991–997.
43. Wonn S.M., Limbach K.E., Pommier S.J. et al. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors // Surgery. 2020. Vol. 169, No. 1. Р. 168–174. doi: 10.1016/j.surg.2020.03.030.
44. Gilly F.N., Cotte E., Brigand C. et al. Quantitative prognostic indices in peritoneal carcinomatosis // Eur. J. Surg. Oncol. 2006. Vol. 32. Р. 597–601.
45. Sadeghi B., Arvieux C., Glehen O. et al. Peritoneal carcinomatosis from non- gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study // Cancer. 2000. Vol. 88. Р. 358–363.
46. De Mestier L., Lardière-Deguelte S., Brixi H. et al. Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors // Neuroendocrinology. 2015. Vol. 101. Р. 105–111. doi.org/10.1159/000371817.
47. Elias D., David A., Sourrouille I. et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases) // Surgery. 2014. Vol. 155. Р. 5–12. doi.org/10.1016/j.surg.2013.05.030.
48. Kianmanesh R., Ruszniewski P., Rindi G. et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors // Neuroendocrinology. 2010. Vol. 91. Р. 333–340. doi.org/10.1159/000286700.
49. Woltering E.A., Voros B.A., Beyer D.T. et al. Aggressive surgical approach to the management of neuroendocrine tumors: a report of 1,000 surgical cytoreductions by a single institution // J. Am. Coll Surg. 2017. Vol. 224. Р. 434–447.
50. Scott A.Е., Pelletier D., Maxwell J.E. et al. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors // Ann. Surg. Oncol. 2019. Vol. 26, No. 8. Р. 2525–2532. doi: 10.1245/s10434-019-07370-3.
51. Saxena A., Chua T.C., Perera M. et al. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review // Surg. Oncol. 2012. Vol. 21, No. 3. Р. 131–141. doi: 10.1016/j.suronc.2012.05.001.
Review
For citations:
Dinikin M.S., Ivanova A.K., Orlova R.V., Pelipas Yu.V. Debulking surgery for small intestine neuroendocrine tumors. Clinical Case in Oncology. 2024;2(4):52-66. (In Russ.) https://doi.org/10.62546/3034-1477-2024-2-4-52-66
Views:
74
Email this article 